29 results
8-K
EX-99.1
GRNA
GreenLight Biosciences Inc
11 May 23
GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:17am
, leveraging scientific expertise, global partnerships, and the power of our platform to progress innovative RNA-based products for plant health and human
424B3
GRNA
GreenLight Biosciences Inc
6 Oct 22
Prospectus supplement
5:15pm
business.
Our dsRNA and mRNA product candidates are based on innovative technologies and any product candidates we develop may be more complex and more … platforms are innovative and complex. There are no mRNA medicines currently manufactured at commercial scale utilizing our manufacturing process. Due
8-K
EX-99.1
GRNA
GreenLight Biosciences Inc
15 Aug 22
GreenLight Biosciences Announces Second Quarter 2022 Financial
6:07pm
Innovative Products That Answer Farmer Challenges; 3. https://www.syngenta-us.com/thrive/research/step-changes.html; 4. 2021 Bayer Annual Report © 2022
424B3
GRNA
GreenLight Biosciences Inc
7 Apr 22
Prospectus supplement
4:02pm
the facility, which could be disruptive to our business.
Our dsRNA and mRNA product candidates are based on innovative technologies and any product candidates … product candidates using our dsRNA and mRNA platforms are innovative and complex. There are no mRNA medicines currently manufactured at commercial
POS AM
nul 5svj87v3qt
5 Apr 22
Prospectus update (post-effective amendment)
5:18pm
424B3
c8xzbg5
15 Feb 22
Prospectus supplement
1:38pm
425
pdh0tdpt84lgy
20 Jan 22
Business combination disclosure
9:38pm
424B3
tvzzumql296cgvpyf2gu
13 Jan 22
Prospectus supplement
4:13pm
CORRESP
12bjdma
6 Dec 21
Correspondence with SEC
12:00am
UPLOAD
fo97yfwf
3 Nov 21
Letter from SEC
12:00am
425
u5s4659q4l97
20 Oct 21
Business combination disclosure
9:30pm
8-K
EX-99.1
qkuufv9hmyxcadxxk
19 Oct 21
Regulation FD Disclosure
2:22pm
S-4/A
EX-10.21
0antiq7fwjt2fex3du8q
19 Oct 21
Registration of securities issued in business combination transactions (amended)
7:58am